Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Click to copy

Press release content from Business Wire. The AP news staff was not involved in its creation.

Click to copy

Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

PRESS RELEASE: Paid content from Business Wire

Press release content from Business Wire. The AP news staff was not involved in its creation.

January 3, 2023 GMT

WATERTOWN, Mass.--(BUSINESS WIRE)--Jan 3, 2023--

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on January 10, 2023 at 3:00 p.m. PT.

A live webcast of the presentation will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 30 days.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com:https://www.businesswire.com/news/home/20230103005027/en/

CONTACT: Media and Investor Contact:

Jennifer Viera

617-744-3848

jviera@enanta.com

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH COVID-19 INFECTIOUS DISEASES CLINICAL TRIALS

SOURCE: Enanta Pharmaceuticals, Inc.

PUB: 01/03/2023 07:00 AM/DISC: 01/03/2023 07:01 AM

http://www.businesswire.com/news/home/20230103005027/en